Leukocyte L1 Antigen Complex
"Leukocyte L1 Antigen Complex" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the S-100 protein family that is present at high levels in the blood and interstitial fluid in several infectious, inflammatory, and malignant disorders, including rheumatoid arthritis, inflammatory bowel disease, and cystic fibrosis. It is a complex of a light chain (CALGRANULIN A) and a heavy chain (CALGRANULIN B). L1 binds calcium through an EF-hand motif, and has been shown to possess antimicrobial activity.
| Descriptor ID |
D039841
|
| MeSH Number(s) |
D12.776.157.125.750.500 D12.776.631.655.500 D23.050.301.562
|
| Concept/Terms |
Leukocyte L1 Antigen Complex- Leukocyte L1 Antigen Complex
- Calcium-Binding Myeloid Protein P8,14
- Calcium Binding Myeloid Protein P8,14
- Calgranulin
- Calprotectin
- Migratory Inhibitory Factor-Related Protein MRP
- Migratory Inhibitory Factor Related Protein MRP
- Myelomonocytic Antigen L1
- Antigen L1, Myelomonocytic
- L1 Antigen
- Antigen, L1
- 27E10 Antigen
- Antigen, 27E10
- Leukocyte L1 Protein
- L1 Protein, Leukocyte
|
Below are MeSH descriptors whose meaning is more general than "Leukocyte L1 Antigen Complex".
Below are MeSH descriptors whose meaning is more specific than "Leukocyte L1 Antigen Complex".
This graph shows the total number of publications written about "Leukocyte L1 Antigen Complex" by people in this website by year, and whether "Leukocyte L1 Antigen Complex" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 2 | 3 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 4 | 4 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukocyte L1 Antigen Complex" by people in Profiles.
-
Coordinated adaptation of Staphylococcus aureus to calprotectin-dependent metal sequestration. mBio. 2024 Jul 17; 15(7):e0138924.
-
Development of Luminescent Biosensors for Calprotectin. ACS Chem Biol. 2024 Jun 21; 19(6):1250-1259.
-
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.
-
Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes. ACS Infect Dis. 2023 10 13; 9(10):1815-1820.
-
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
-
Patient-Reported Outcomes Correlate With Microbial Community Composition Independent of Mucosal Inflammation in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 02 01; 29(2):286-296.
-
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022 10 03; 28(10):1549-1554.
-
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
-
Molecular Basis of Ca(II)-Induced Tetramerization and Transition-Metal Sequestration in Human Calprotectin. J Am Chem Soc. 2021 11 03; 143(43):18073-18090.
-
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129.